President Joe Biden’s proposal to invest more in mental health should compliment an effort by health insurers to integrate behavioral care with medical treatment.

InnovationRx is your weekly digest of healthcare news. Sign up!

Johnson & Johnson’s Covid-19 vaccine was far less effective at keeping people out of hospital than the Pfizer-BioNTech shot, according to a peer reviewed study published in JAMA Network Open Wednesday.

The White House’s new “National Covid-19 Preparedness Plan,” unveiled Wednesday, focuses heavily on prevention amid declining numbers of cases, and looks forward to future variants.

Build Back Better probably isn’t completely dead. Parts of it may be resurrected. Given its bipartisan support, it’s likely that Medicare Part D restructuring would constitute an integral component of any passable legislation, which would likely exert downward pressure on drug prices.

Though less effective than Pfizer’s shot, the risk of hospitalization is still significantly higher for unvaccinated people.

Self-sufficiency is a prime objective

New research indicates that SARS-CoV-2 may be able to impact viral pathogenesis without entering host cells— extracellular binding of the spike protein to host ACE2 has the potential to alter both cell physiology and expression of viral proteins.

U.S. policy has come a long way from just two years ago when government officials declared that the pricing and affordability of Covid-19 vaccines should be left to the free market. Not ensuring affordability would have implied that ability to pay would determine who gets vaccine access.

What happens when two organizations join forces on the promise of delivering pricing transparency for the nation…except instead of price transparency, what’s delivered is price obfuscation? To borrow from Katherine Gehl, the system isn’t broken. It’s fixed.